Jorge Cortes, MD, Georgia Cancer Center

Closing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.

Moshe Talpaz, MD, discusses best practices in monitoring patients with CML and applying multidisciplinary care.

Daniel DeAngelo, MD, PhD, provides his perspective on improving CML care through dose adjustment or treatment discontinuation.

An overview of the general toxicities patients may experience while undergoing therapy for chronic myeloid leukemia.

A brief review of asciminib’s toxicity profile and how to best manage adverse events in patients with chronic myeloid leukemia.

Experts share their personal experience with asciminib as later-line therapy for patients with chronic myeloid leukemia.

Shared insight on asciminib’s role in chronic myeloid leukemia in light of available clinical data.

Jorge Cortes, MD, breaks down third-line treatment options for patients who progress with chronic myeloid leukemia.

A brief review of the inherent challenges in guiding patients through several lines of therapy for chronic myeloid leukemia.

Considerations for selecting optimal second-line therapy for chronic myeloid leukemia when a patient progresses.

Daniel DeAngelo, MD, PhD, highlights the role that tyrosine kinase inhibitors play in the CML treatment paradigm.

Key opinion leader perspectives on assessing a patient’s response to therapy for chronic myeloid leukemia.

Shared insight on chromosomal abnormalities and genetic alterations that influence the disease course and management of CML.

Expert overview of chronic myeloid leukemia, including considerations for the unmet needs in management as they exist today.

Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).

Robin Foà, MD, discusses results from the GIMEMA LAL2317 sequential chemotherapy-blinatumomab frontline trial, where experts evaluated the efficacy of blinatumomab in increasing the early MRD (minimal residual disease) negativity rate.

Elias Jabbour, MD, highlights early findings from a phase 2 study of the combination of ponatinib and blinatumomab in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Jorge Cortes, MD, reviews the results of the OPTIC trial: a dose-optimization study of 3 starting doses of ponatinib.